Database : MEDLINE
Search on : Neurodermatitis [Words]
References found : 17437 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1744 go to page                         

  1 / 17437 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 28747736
[Au] Autor:Li Y; Cheng H; Xiao FL; Liang B; Zhou FS; Li P; Zheng XD; Sun LD; Yang S; Zhang XJ
[Ad] Address:Institute of Dermatology and Department of Dermatology, No.1 Hospital, Anhui Medical University, Hefei, Anhui, China.
[Ti] Title:Association of UBASH3A gene polymorphism and atopic dermatitis in the Chinese Han population.
[So] Source:Genes Immun;18(3):158-162, 2017 09.
[Is] ISSN:1476-5470
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Genome-wide association studies have revealed a large number of genetic-risk loci for many autoimmune diseases. One clear finding emerging from the published genetic studies of autoimmunity is that different autoimmune diseases share susceptibility loci. Recent evidence has demonstrated that UBASH3A gene was associated with multiple autoimmune diseases. The aim of this study was to explore the association between UBASH3A single-nucleotide polymorphisms (SNPs) and atopic dermatitis (AD) in a Chinese Han population. In total, three UBASH3A SNPs (rs11203203, rs3788013 and rs1893592) were genotyped using TaqMan genotyping assays in a Chinese Han population (1012 cases and 1362 controls). Among these SNPs, we selected the SNP rs1893592 with association values of P<5 × 10 for AD in the TaqMan genotyping assay data for further replication in the independent Chinese replication samples (1080 cases and 1367 controls) using a Sequenom MassARRAY system. We combined the association results in two stages using meta-analysis. We found that rs1893592 in UBASH3A showed association with AD (P=1.29 × 10 , odds ratio=1.16). These results showed that UBASH3A gene SNP is associated with susceptibility to AD. Further fine mapping and functional studies will be required to identify true causal variant in the UBASH3A gene and its exact role in the pathogenesis of AD.
[Mh] MeSH terms primary: Adaptor Proteins, Signal Transducing/genetics
Dermatitis, Atopic/genetics
Polymorphism, Single Nucleotide
[Mh] MeSH terms secundary: Adult
Case-Control Studies
Child
Child, Preschool
China
Female
Humans
Infant
Male
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Adaptor Proteins, Signal Transducing); 0 (UBASH3A protein, human)
[Em] Entry month:1802
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:IM
[Da] Date of entry for processing:170728
[St] Status:MEDLINE
[do] DOI:10.1038/gene.2017.15

  2 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29292947
[Au] Autor:Ståhle M; Bradley M
[Ad] Address:Karolinska Universitetssjukhuset - Hudkliniken Stockholm, Sweden Karolinska Universitetssjukhuset - Hudkliniken Stockholm, Sweden.
[Ti] Title:Komplexa diagnoser med samsjuklighet.
[So] Source:Lakartidningen;114, 2017 11 21.
[Is] ISSN:1652-7518
[Cp] Country of publication:Sweden
[La] Language:swe
[Mh] MeSH terms primary: Dermatitis, Atopic/diagnosis
Psoriasis/diagnosis
[Mh] MeSH terms secundary: Comorbidity
Dermatitis, Atopic/epidemiology
Dermatitis, Atopic/therapy
Humans
Psoriasis/epidemiology
Psoriasis/therapy
[Pt] Publication type:INTRODUCTORY JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:180103
[St] Status:MEDLINE

  3 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29292944
[Au] Autor:Bradley M; Wahlgren CF
[Ad] Address:Institutionen för Medicin - Hudkliniken, Karolinska i Solna Stockholm, Sweden Institutionen för Medicin - Department of dermatology Stockholm, Sweden.
[Ti] Title:Nya läkemedel mot atopiskt eksem väntar på godkännande - Bättre förståelse av den molekylära sjukdomsmekanismen kan ge fler och bättre verktyg för behandling.
[So] Source:Lakartidningen;114, 2017 Nov 21.
[Is] ISSN:1652-7518
[Cp] Country of publication:Sweden
[La] Language:swe
[Ab] Abstract:New treatments for atopic dermatitis Atopic dermatitis is one of the most common skin disorders in Sweden. The pathogenesis is a complex counterplay between a defect skin barrier and an abnormal immune response that can be caused by genetic and/or environmental factors. Atopic dermatitis has a huge negative impact on quality of life. New and more specific treatments are under way and hopefully we will, in the near future, better treat even the more severe cases of atopic dermatitis.
[Mh] MeSH terms primary: Dermatitis, Atopic/drug therapy
Dermatologic Agents/therapeutic use
[Mh] MeSH terms secundary: Antibodies, Monoclonal/therapeutic use
Boron Compounds/therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use
Dermatitis, Atopic/metabolism
Dermatitis, Atopic/physiopathology
Drug Approval
Emollients/therapeutic use
Humans
Skin/metabolism
Skin/physiopathology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antibodies, Monoclonal); 0 (Boron Compounds); 0 (Bridged Bicyclo Compounds, Heterocyclic); 0 (Dermatologic Agents); 0 (Emollients)
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:180103
[St] Status:MEDLINE

  4 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29292940
[Au] Autor:Johansson E
[Ad] Address:Karolinska Institutet - Enheten för dermatologi och venereologi, Institutionen för medicin Solna Stockholm, Sweden Karolinska Institutet - Enheten för dermatologi och venereologi, Institutionen för medicin Solna Stockholm, Sweden.
[Ti] Title:Atopiskt eksem vanligt i alla åldrar - Nya rön om samsjuklighet till atopiskt eksem.
[So] Source:Lakartidningen;114, 2017 Nov 21.
[Is] ISSN:1652-7518
[Cp] Country of publication:Sweden
[La] Language:swe
[Ab] Abstract:Atopic eczema common at all ages Eczema (atopic dermatitis) is an inflammatory skin disorder with dry skin and recurrent episodes of inflammation and itch. Onset is most common the first two years of life, but also occurs among older children, adolescents and adults. The prevalence of eczema has increased in Sweden and other industrialized countries the last decades; 15-30% of children and 2-10% of adults are affected. Approximately half of children with eczema early in life are in remission in adolescence. However, many of these will relapse later in life, often as hand eczema. Children with eczema are at increased risk to develop IgE sensitization to common food- and airborne allergens, food allergy, asthma and rhinitis. In addition, recent studies have reported that having eczema is associated with non-allergic disorders such as ADHD, depression and anxiety, epilepsy, overweight and obesity, cardiovascular disease, and different kinds of malignancies. There are also studies that have not found an association between eczema and the above mentioned non-allergic comorbidities. Thus, the association between eczema and non-allergic comorbidities are still largely unknown.
[Mh] MeSH terms primary: Dermatitis, Atopic
[Mh] MeSH terms secundary: Adolescent
Adult
Age Factors
Aged
Asthma/epidemiology
Attention Deficit Disorder with Hyperactivity/epidemiology
Child
Child, Preschool
Comorbidity
Dermatitis, Atopic/diagnosis
Dermatitis, Atopic/epidemiology
Dermatitis, Atopic/etiology
Dermatitis, Atopic/pathology
Humans
Immunoglobulin E/immunology
Infant
Middle Aged
Rhinitis/epidemiology
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:37341-29-0 (Immunoglobulin E)
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[Js] Journal subset:IM
[Da] Date of entry for processing:180103
[St] Status:MEDLINE

  5 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28460633
[Au] Autor:Zhang Z; Zheng W; Xie H; Chai R; Wang J; Zhang H; He S
[Ad] Address:Allergy and Clinical Immunology Research Centre, The First Affiliated Hospital of Jinzhou Medical University, No. 2, Section 5, Renmin Street, Guta District, Jinzhou, 121001, Liaoning, People's Republic of China.
[Ti] Title:Up-regulated expression of substance P in CD8 T cells and NK1R on monocytes of atopic dermatitis.
[So] Source:J Transl Med;15(1):93, 2017 May 01.
[Is] ISSN:1479-5876
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Large numbers of CD8 T cells were observed in atopic dermatitis (AD) skin, and monocytes from AD patients showed increased prostaglandin E2 production. However, little is known about the expression of substance P (SP) and its receptor NK1R in blood leukocytes of patients with AD. OBJECTIVE: To explore the expression of SP and NK1R in leukocytes of AD and the influence of allergens on SP and NK1R expression. METHODS: The expression levels of SP and NK1R in patients with AD were examined by flow cytometry, ELISA and a mouse AD model. RESULTS: The plasma SP level was 4.9-fold higher in patients with AD than in HC subjects. Both the percentage of SP expression in the population and mean fluorescence intensity (MFI) of SP expression were elevated in CD8 T cells in the blood of AD patients. However, both the CD14 NK1R population and MFI of NK1R expression on CD14 cells were enhanced in the blood of AD patients. Allergens ASWE, HDME and PPE failed to up-regulate SP expression in CD8 T cells. However, allergens ASWE and HDME both enhanced NK1R expression on CD14 blood leukocytes regardless of AD or HC subjects. OVA-sensitized AD mice showed an elevated proportion and MFI of SP-expressing CD8 T cells in the blood, which agrees with the SP expression situation in human AD blood. Injection of SP into mouse skin did not up-regulate NK1R expression on monocytes. CONCLUSIONS: An elevated plasma SP level, up-regulated expression of SP and NK1R indicate that the SP/NK1R complex is important in the development of AD. Therefore, SP and NK1R antagonist or blocker agents may help to treat patients with AD. Trial registration Registration number: ChiCTR-BOC-16010279; Registration date: Dec., 28, 2016; retrospectively registered.
[Mh] MeSH terms primary: CD8-Positive T-Lymphocytes/immunology
Dermatitis, Atopic/genetics
Dermatitis, Atopic/immunology
Monocytes/pathology
Receptors, Neurokinin-1/metabolism
Substance P/genetics
Up-Regulation/genetics
[Mh] MeSH terms secundary: Adolescent
Adult
Aged
Allergens/immunology
Animals
Case-Control Studies
Dermatitis, Atopic/blood
Flow Cytometry
Humans
Mice, Inbred BALB C
Middle Aged
Ovalbumin/immunology
Substance P/blood
Substance P/metabolism
Young Adult
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Allergens); 0 (Receptors, Neurokinin-1); 33507-63-0 (Substance P); 9006-59-1 (Ovalbumin)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:170503
[St] Status:MEDLINE
[do] DOI:10.1186/s12967-017-1196-6

  6 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29353721
[Au] Autor:Purushothaman B; Arumugam P; Kulsi G; Song JM
[Ad] Address:College of Pharmacy, Seoul National University, Seoul 151-742, South Korea.
[Ti] Title:Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis.
[So] Source:Eur J Med Chem;145:673-690, 2018 Feb 10.
[Is] ISSN:1768-3254
[Cp] Country of publication:France
[La] Language:eng
[Ab] Abstract:Selective inhibition of phosphodiesterase (PDE) 4B favorably suppresses the synthesis of inflammatory cytokines and subsequently arrest the development of atopic dermatitis via modulating the intracellular cAMP levels. Considering the side effects of corticosteroids, selective PDE4 inhibition could constitute an effective alternative therapy for the treatment of atopic dermatitis (AD). In this study, a series of novel catechol based compounds bearing pyrimidine as the core have been synthesized and screened for the PDE4 inhibitory properties. The PDE4 selectivity of the active compounds over other PDEs has been investigated. Compound 23 bearing pyrimidine core functionalized with catechol, pyridine and trifluoromethyl groups can effectively inhibit the PDE4B with IC value in nanomolar range (IC = 15 ±â€¯0.4 nM). Compound 23 exhibited seven fold higher selectivity towards PDE4B over PDE4D. Molecular Docking study confirmed its stronger affinity towards catalytic domain of PDE4B. In-vivo analysis confirmed that compound 23 effectively alleviated the symptoms of atopic dermatitis in DNCB-treated Balb/c mice by suppressing the synthesis of inflammatory mediators such as TNF-α, and Ig-E. Taken together, this study suggested that compound 23 could be an effective PDE4 inhibitor for the potential treatment of AD.
[Mh] MeSH terms primary: Catechols/pharmacology
Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism
Dermatitis, Atopic/drug therapy
Drug Design
Phosphodiesterase 4 Inhibitors/pharmacology
Pyrimidines/pharmacology
[Mh] MeSH terms secundary: Animals
Catechols/chemical synthesis
Catechols/chemistry
Crystallography, X-Ray
Dermatitis, Atopic/metabolism
Dermatitis, Atopic/pathology
Dose-Response Relationship, Drug
Male
Mice
Mice, Inbred BALB C
Models, Molecular
Molecular Structure
Phosphodiesterase 4 Inhibitors/chemical synthesis
Phosphodiesterase 4 Inhibitors/chemistry
Pyrimidines/chemical synthesis
Pyrimidines/chemistry
Structure-Activity Relationship
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Catechols); 0 (Phosphodiesterase 4 Inhibitors); 0 (Pyrimidines); EC 3.1.4.17 (Cyclic Nucleotide Phosphodiesterases, Type 4)
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:IM
[Da] Date of entry for processing:180123
[St] Status:MEDLINE

  7 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29386434
[Au] Autor:Watanabe K
[Ad] Address:Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences.
[Ti] Title:[From a Ph.D. Thesis: Understanding the Past, Predicting the Future].
[So] Source:Yakugaku Zasshi;138(2):211-219, 2018.
[Is] ISSN:1347-5231
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract: Posey et al. have reported multiple molecular diagnoses in 4.5% of cases (101/2076) in which whole-exome sequencing was informative. Distinct disease phenotypes affect different organ systems, whereas overlapping disease phenotypes are more likely to be caused by two genes encoding proteins that interact within the same pathway. My research projects at the Niigata University of Pharmacy have investigated underlying mechanisms involved in human disease, including fatty acid metabolism, diabetic cardiomyopathy, atopic dermatitis, colitis, hepatitis, etc. Three students from abroad graduated this year from the Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences. These students reported on treatments for heart disease, non-alcoholic steatohepatitis and atopic dermatitis, as well as the underlying mechanisms involved in each. The titles of these reports are "Study of the role of cardiac 14-3-3η protein in cardiac inflammation and adverse cardiac remodeling during heart failure in mice", "Non-alcoholic steatohepatitis: onset of mechanisms under diabetic background and treatment strategies" and "The role of HMGB1 and its cascade signaling pathway in atopic dermatitis". It can be concluded from these three theses that oxidative stress and inflammation are among the principal mechanisms underlying these diseases.
[Mh] MeSH terms primary: Dermatitis, Atopic
HMGB1 Protein
Heart Failure
Non-alcoholic Fatty Liver Disease
[Mh] MeSH terms secundary: 14-3-3 Proteins
AMP-Activated Protein Kinases
Animals
Dermatitis, Atopic/genetics
Diabetes Complications
Endoplasmic Reticulum Stress
Heart Failure/genetics
Humans
Mice
Non-alcoholic Fatty Liver Disease/etiology
Non-alcoholic Fatty Liver Disease/therapy
Oxidative Stress
Pathology, Molecular
Whole Exome Sequencing
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (14-3-3 Proteins); 0 (HMGB1 Protein); EC 2.7.11.31 (AMP-Activated Protein Kinases)
[Em] Entry month:1802
[Cu] Class update date: 180228
[Lr] Last revision date:180228
[Js] Journal subset:IM
[Da] Date of entry for processing:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00111

  8 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29367526
[Au] Autor:Ishitsuka Y
[Ad] Address:Department of Dermatology, Faculty of Medicine, University of Tsukuba.
[Ti] Title:[The formation of skin barrier and defective barrier-associated skin diseases].
[So] Source:Nihon Rinsho Meneki Gakkai Kaishi;40(6):416-427, 2017.
[Is] ISSN:1349-7413
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:  Since the discovery of loss-of-function mutations in filaggrin (FLG) gene in atopic dermatitis (AD) individuals, significant attention has been paid against the skin barrier as an initial starting point of atopic march. Although FLG is a significant cornification-associated gene, skin barrier formation is a complex process mediated by an array of genes with specific functions. In this article, the mechanism of physical skin barrier formation is reviewed in detail, focusing on specific gene functions and inherited disorders caused by genetic aberrations. Additionally, the mechanism of percutaneous sensitization with environmental allergens in association with FLG-deficiency is reviewed in order to clarify the link between defective skin barrier and atopic march. Finally, updated knowledge of psoriasis pathophysiology in connection with genetic defect in skin barrier is reviewed. This article would provide a novel opportunity to understand the allergic/autoimmune disorders from the viewpoint of non-classical immune cells.
[Mh] MeSH terms primary: Skin Diseases/genetics
Skin Diseases/immunology
Skin/immunology
[Mh] MeSH terms secundary: Dermatitis, Atopic/genetics
Dermatitis, Atopic/immunology
Humans
Intermediate Filament Proteins/genetics
Loss of Function Mutation
Psoriasis/genetics
Psoriasis/immunology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Intermediate Filament Proteins); 0 (filaggrin)
[Em] Entry month:1802
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[Js] Journal subset:IM
[Da] Date of entry for processing:180126
[St] Status:MEDLINE
[do] DOI:10.2177/jsci.40.416

  9 / 17437 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29470609
[Au] Autor:Werfel T; Wollenberg A; Pumnea T; Heratizadeh A
[Ad] Address:Abteilung für Immundermatologie und experimentelle Allergologie, Klinik für Dermatologie, Allergologie und Venerologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
[Ti] Title:Neues in der Systemtherapie der atopischen Dermatitis. [New aspects in systemic treatment of atopic dermatitis].
[So] Source:Hautarzt;, 2018 Feb 22.
[Is] ISSN:1432-1173
[Cp] Country of publication:Germany
[La] Language:ger
[Ab] Abstract:In severe cases of atopic dermatitis (AD) systemic treatment is indicated. So far, cyclosporine and systemic glucocorticosteroids represented the only systemic treatment options approved for the indications of AD in Germany; however, from clinical practice there is increasing evidence for beneficial therapeutic effects in AD by other immunosuppressive or immunomodulatory substances, such as mycophenolate, methotrexate, alitretinoin and ustekinumab. Beyond this, ongoing research activities focus on a better understanding of genetic and immunological aspects of this chronic inflammatory skin disease. Regarding treatment with mycophenolate, genetic polymorphisms in AD patients could be identified that might predict responsiveness to this medication. Moreover, several new substances specifically targeting inflammation in AD are currently being studied and the first promising treatment effects on skin condition and pruritic symptoms of AD could be observed. As an exceptional result of this development in September 2017 in Europe and therefore in Germany the first biologic as first-line treatment was approved for the indication of moderate to severe AD in adults. Dupilumab is a human monoclonal IgG4 antibody that blocks a subunit of the interleukin (IL)-4 and IL-13 receptors, thus inhibiting the proinflammatory effects of these cytokines. Furthermore, the cytokine IL-13 itself, the IL-31 receptor, which is of particular relevance for pruritus in AD, the histamine-4-receptor and Janus kinases represent further promising targets currently being investigated in clinical trials for the treatment of AD.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Em] Entry month:1802
[Cu] Class update date: 180222
[Lr] Last revision date:180222
[St] Status:Publisher
[do] DOI:10.1007/s00105-018-4131-8

  10 / 17437 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29297666
[Au] Autor:Pikina AP; Shkoporov AN; Kulagina EV; Khokhlova EV; Chaplin AV; Volodin NN; Kafarskaya LI; Korotkly NG; Efimov BA
[Ti] Title:Comparative Genotyping of Staphylococcus aureus Strains Isolated from Skin Lesions, Nasal Cavities, and Feces of Children with Atopic Dermatitis.
[So] Source:Vestn Ross Akad Med Nauk;71(5):367-74, 2016.
[Is] ISSN:0869-6047
[Cp] Country of publication:Russia (Federation)
[La] Language:eng
[Ab] Abstract:Background: The lesion of skin of the majority atopic dermatitis patients is chronically colonized by bacteria belonging to the species Staphylococcus aureus. Topical antibacterial and anti-inflammatory therapy treatment are often ineffective due to fast recolonization by S. aureus and exacerbation of allergic process. Aims: Our aim was to determine a frequency of S. aureus colonization in skin lesions, mucous membranes of the nasal cavity and intestine of children with atopic dermatitis, to compare the genotypes of Staphylococcus aureus strains isolated from different biotopes of atopic dermatitis patients, and to clarify whether the intestinal and nasal cavities microbiota may act as a source of S. aureus recolonization of skin lesions. Materials and Methods: Bacteriological examination of fecal samples, skin, and nasal swabs was conducted in 38 atopic dermatitis patients. The pure bacterial cultures of S. aureus were identified using API Staph (Biomerieux, France) and Vitek 2 MS (Biomerieux, France). Isolates of S. aureus were subjected to genotyping by analysis of rRNA internal 16S-23S rRNA spacer regions and high resolution melting analysis (HMR) of polymorphic spa X-regions. Results: 99% S. aureus strains were successfully identified using MALDI-TOF mass-spectrometry. S. aureus cultures were isolated from all biotopes in 31,6% of children, from skin and nasal cavities ­ in 42% of cases, from skin and feces ­ in 2,6% of cases, only from skin ­ in 10,5%, from nasal cavities and feces ­ in 2,6%, and only from nasal cavities ­ in 2,6% of cases. In 8% of children, S. aureus was not detected in any of the biotopes. Genotyping of the isolates enabled the detection of 17 different genotypes. A match between the genotypes of skin and nasal strains, and skin and fecal strains was observed in 88% and 61% of the cases respectively. Conclusions: The observed a high-frequency matching genotypes suggests the possibility of migration of S. aureus strains inside biotopes in humans and the absence of specialization to colonization of any of the niches.
[Mh] MeSH terms primary: Dermatitis, Atopic/microbiology
Feces/microbiology
Genotype
Nasal Cavity/microbiology
Skin/microbiology
Staphylococcus aureus
[Mh] MeSH terms secundary: Bacteriological Techniques/methods
Child
Colony Count, Microbial/methods
Female
Humans
Male
Staphylococcus aureus/genetics
Staphylococcus aureus/isolation & purification
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180220
[Lr] Last revision date:180220
[Js] Journal subset:IM
[Da] Date of entry for processing:180104
[St] Status:MEDLINE
[do] DOI:10.15690/vramn695


page 1 of 1744 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information